solute carrier family 18 member B1Genealiases: C6orf192 · VPAT · dJ55C23.6
Q-omics provides the consensus-scored SLC18B1 profile across patient tissues and cancer cell-line models. SLC18B1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SLC18B1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SLC18B1 RNA expression shows 20,039 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where SLC18B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC18B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC18B1 survival associations across molecular data types. SLC18B1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC18B1 RNA expression–survival associations across cancer types. High SLC18B1 expression shows unfavorable associations in LUAD, LIHC and KIRP, but favorable associations in READ, HNSC and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SLC18B1 RNA expression.
This table summarizes SLC18B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC18B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC18B1 shows lower tumor expression in KIRC, THCA, HNSC and KICH and higher tumor expression in LIHC and STAD. The KIRC box plot shows higher SLC18B1 RNA expression in normal versus tumor tissue (log2 FC = −0.885, t-test p < 0.001).
This table shows molecular features associated with SLC18B1 in patient tissues and cancer cell lines. In patient samples, SLC18B1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC18B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
